Akeso reported interim Phase 3 HARMONi-2 results in China showing its ivonescimab PD-1/VEGF bispecific improved overall survival and progression-free survival versus Merck’s Keytruda in first-line NSCLC with PD-L1–expressing tumors. The data builds on prior PFS success. Analysts note the global HARMONi-3 trial will be critical, with concerns about FDA accelerated approval impact if benefits aren’t sufficient.
ABOUT
Most feeds treat all company headlines the same. An executive interview, an office closure, stock analysis, and a data breach can sit side by side with no sense of scale. Fimmer ranks coverage by what matters, so important events stand out and signals are prioritised over noise. We cluster related company news and score each story using a range of metrics, so you see the most crucial stories first.
SCORING
Significance (0–10) measures the scale of the real-world impact. Sentiment and ESG (−10 to +10) indicate the tone of the coverage and whether the change relates to environmental, social, or governance factors. Together, these scores help distinguish meaningful developments from routine company news. More information about our scoring methodology can be found on our About page.
DISCOVERY
Search more than 10,000 public companies, browse the company index, explore their scores, and read the coverage behind them, with our core features available to everyone for free.
For more advanced features, Pro gives you access to dynamic feeds, custom sorting, and more ways to track the companies that matter to you.
